September 15, 2022 — Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, will showcase its latest innovations and cardiology solutions designed to strengthen clinical confidence, build efficiency throughout the care pathway and improve cardiac care experiences at the Transcatheter Cardiovascular Therapeutics

September 15, 2022 - Happitech has announced the launch of its FastStart Research app. The Amsterdam-based digital health company designed the app to support researchers and advance the adoption of digital health technology in cardiac practice.

September 15, 2022 — Cardiac Implants LLC has announced the successful initial deployment of its Annuloplasty ring with implementation of a therapeutic adjustment procedure using its innovative Tri-Ring percutaneous annuloplasty device.

September 14, 2022 — Minimally invasive, catheter-based transcatheter aortic valve replacement (TAVR) has revolutionized treatment of aortic stenosis (AS), and both American and European guidelines have approved its use. However, there is a perception that TAVR is more expensive than surgical aortic valve replacement (SAVR).

September 14, 2022 — GE Healthcare and Lantheus Holdings Inc have announced that the recent Phase III clinical trial of their investigational radiotracer, [18F]flurpiridaz, has met its co-primary endpoints of exceeding a 60 percent threshold for both sensitivity and specificity for detecting 

September 14, 2022 — In recognition of Atrial Fibrillation (AFib) Awareness Month, Biosense Webster, Inc., part of Johnson & Johnson MedTech†, released findings from an AFib PulseCheck Survey that reveals AFib patient behaviors and their understanding of AFib treatment optio

September 14, 2022 — Details on late-breaking clinical trials to be presented during The VEINS (Venous Endovascular INterventional Strategies) and VIVA  (Vascular InterVentional Advances) Annual Conference have been announced.

September 13, 2022 — Anthos Therapeutics, a clinical-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, has announced that the U.S.

September 13, 2022 — ZOLL Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that the first patient has enrolled in the AMIHOT III post-approval study further evaluating 

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now